NEW YORK — French diagnostics firm Theradiag said on Monday that it has received CE marks for four of its i-Tracker biotherapy monitoring test kits.
The newly CE-marked kits include i-Tracker Vedolizumab, i-Tracker Anti-Vedolizumab, i-Tracker Ustekinumab, and i-Tracker Anti-Ustekinumab, which are used to monitor the levels of drugs used to treat chronic gastrointestinal inflammatory conditions including Crohn's disease and ulcerative colitis.